Syndax [SNDX] vs Harmony Biosciences [HRMY] Detailed Stock Comparison

Syndax

NASDAQ
Loading...

Harmony Biosciences

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Syndax wins in 6 metrics, Harmony Biosciences wins in 12 metrics, with 0 ties. Harmony Biosciences appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricSyndaxHarmony BiosciencesBetter
P/E Ratio (TTM)-4.1810.45Syndax
Price-to-Book Ratio8.502.41Harmony Biosciences
Debt-to-Equity Ratio219.4922.43Harmony Biosciences
PEG Ratio-1.110.04Syndax
EV/EBITDA-3.595.99Syndax
Profit Margin (TTM)96.51%23.42%Syndax
Operating Margin (TTM)-182.71%24.03%Harmony Biosciences
EBITDA Margin (TTM)N/A24.03%N/A
Return on Equity-113.22%27.58%Harmony Biosciences
Return on Assets (TTM)-39.50%14.10%Harmony Biosciences
Free Cash Flow (TTM)$-274.90M$218.67MHarmony Biosciences
1-Year Return-18.67%-16.76%Harmony Biosciences
Price-to-Sales Ratio (TTM)17.192.41Harmony Biosciences
Enterprise Value$1.22B$1.47BHarmony Biosciences
EV/Revenue Ratio15.611.91Harmony Biosciences
Gross Profit Margin (TTM)96.63%80.97%Syndax
Revenue per Share (TTM)$1$14Harmony Biosciences
Earnings per Share (Diluted)$-3.89$3.10Harmony Biosciences
Beta (Stock Volatility)0.720.84Syndax
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Syndax vs Harmony Biosciences Stock Performance Analysis

Loading Price Chart...

Syndax
Harmony Biosciences
Syndax Stock Overview | Harmony Biosciences Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Syndax-5.01%-8.74%19.89%45.74%18.52%10.44%
Harmony Biosciences-3.08%-10.00%-8.68%-2.82%-3.60%-7.01%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Syndax-18.67%-32.80%-8.58%31.22%31.22%31.22%
Harmony Biosciences-16.76%-26.12%-3.60%-10.03%-10.03%-10.03%

News Based Sentiment: Syndax vs Harmony Biosciences

Syndax

News based Sentiment: POSITIVE

Syndax reported exceptional Q2 results and continued to showcase strong sales figures throughout September, attracting positive analyst attention. The upcoming FDA decision on October 25, 2025, for Revumenib represents a significant catalyst, but the company still faces challenges in achieving profitability, creating a balanced investment narrative.

View Syndax News Sentiment Analysis

Harmony Biosciences

News based Sentiment: POSITIVE

While the Q2 earnings slightly missed expectations, Harmony Biosciences demonstrated continued progress with its pipeline, reaffirmed its full-year guidance, and maintained strong institutional support. The company's ambitious strategic vision and positive analyst ratings suggest a positive outlook for long-term growth, making September a relatively positive month for investors.

View Harmony Biosciences News Sentiment Analysis

Performance & Financial Health Analysis: Syndax vs Harmony Biosciences

MetricSNDXHRMY
Market Information
Market Cap i$1.34B$1.86B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,760,260893,510
90 Day Avg. Volume i2,610,963646,440
Last Close$15.55$32.39
52 Week Range$8.58 - $22.50$26.47 - $41.61
% from 52W High-30.89%-22.16%
All-Time High$29.86 (Jan 30, 2023)$62.08 (Dec 05, 2022)
% from All-Time High-47.92%-47.83%
Growth Metrics
Quarterly Revenue Growth9.85%0.16%
Quarterly Earnings Growth9.85%2.43%
Financial Health
Profit Margin (TTM) i0.97%0.23%
Operating Margin (TTM) i-1.83%0.24%
Return on Equity (TTM) i-1.13%0.28%
Debt to Equity (MRQ) i219.4922.43
Cash & Liquidity
Book Value per Share (MRQ)$1.83$13.44
Cash per Share (MRQ)$5.44$9.83
Operating Cash Flow (TTM) i$-302,667,008$259.38M
Levered Free Cash Flow (TTM) i$-173,729,744$197.81M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Syndax vs Harmony Biosciences

MetricSNDXHRMY
Price Ratios
P/E Ratio (TTM) i-4.1810.45
Forward P/E i-4.399.94
PEG Ratio i-1.110.04
Price to Sales (TTM) i17.192.41
Price to Book (MRQ) i8.502.41
Market Capitalization
Market Capitalization i$1.34B$1.86B
Enterprise Value i$1.22B$1.47B
Enterprise Value Metrics
Enterprise to Revenue i15.611.91
Enterprise to EBITDA i-3.595.99
Risk & Other Metrics
Beta i0.720.84
Book Value per Share (MRQ) i$1.83$13.44

Financial Statements Comparison: Syndax vs Harmony Biosciences

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)SNDXHRMY
Revenue/Sales i$37.96M$184.73M
Cost of Goods Sold i$1.28M$31.99M
Gross Profit i$36.68M$152.74M
Research & Development i$62.23M$34.54M
Operating Income (EBIT) i$-69.35M$56.25M
EBITDA i$-63.99M$66.98M
Pre-Tax Income i$-71.85M$57.18M
Income Tax iN/A$11.62M
Net Income (Profit) i$-71.85M$45.56M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)SNDXHRMY
Cash & Equivalents i$153.99M$489.00M
Total Current Assets i$548.75M$642.69M
Total Current Liabilities i$94.55M$175.12M
Long-Term Debt i$1.45M$158.18M
Total Shareholders Equity i$215.06M$720.53M
Retained Earnings i$-1.31B$47.78M
Property, Plant & Equipment i$1.80MN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)SNDXHRMY
Operating Cash Flow i$-95.02M$36.44M
Capital Expenditures iN/A$-128,000
Free Cash Flow i$-95.16M$33.86M
Debt Repayment iN/A$-3.75M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSNDXHRMY
Shares Short i20.92M4.33M
Short Ratio i7.208.35
Short % of Float i0.27%0.16%
Average Daily Volume (10 Day) i1,760,260893,510
Average Daily Volume (90 Day) i2,610,963646,440
Shares Outstanding i85.69M57.14M
Float Shares i72.69M50.63M
% Held by Insiders i0.01%0.11%
% Held by Institutions i1.21%0.95%

Dividend Analysis & Yield Comparison: Syndax vs Harmony Biosciences

MetricSNDXHRMY
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A